Bharat Biotech is the third pharmaceutical firm to apply for emergency use authorisation.The Ministry of Health & Family Welfare has said that the media report about the rejection of Bharat Biotech and Serum Institute’s emergency use authorisation of vaccine is fake.
The statement was issued shortly after a couple of media outlets claimed that proposals of Bharat Biotech and Serum institute were not cleared over ‘inadequate safety and efficacy data.’
The media report about the rejection of Serum Institute and Bharat Biotech’s emergency use authorisation of vaccine is fake: Ministry of Health & Family Welfare pic.twitter.com/vysHrU43hi
An expert committee of the Central Drugs Standard Control Organisation (CDSCO) had met earlier in the day to review the emergency use authorisation proposal of COVID-19 vaccine by the Hyderabad-headquartered Bharat Biotech and the Pune’s Serum Institute of India. US-based Pfizer Inc. too has applied for the emergency use authorisation.
Bharat Biotech is the third pharmaceutical firm to apply for emergency use authorisation. While the company has indigenously developed Covaxin, the Serum Institute of India has sought the nod for Oxford University sponsored Covishield which is being developed in partnership with Swedish pharmaceutical firm AstraZeneca.
Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.